Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 360 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
 
BRIEF COMMUNICATION
Ahead of Print

Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity


1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India

Correspondence Address:
Sanjay Kalra,
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Recently reported cardiovascular outcome studies on empagliflozin (EMPA-REG) and liraglutide (LEADER) have spurred interest in this field of diabetology. This commentary compares and contrasts these studies with two equally important outcome trials conducted using blood pressure lowering agents. A comparison with MICROHOPE (using ramipril) and ADVANCE (using perindopril + indapamide) blood pressure arms throws up interesting facts. The degree of blood pressure lowering, dissociation between cardiovascular and cerebrovascular benefits, and discordance between renal and retinal outcomes are surprisingly similar in these trials, conducted using disparate molecules. The time taken to achieve such benefits is similar for all drugs except empagliflozin. Such discussion helps inform rational and evidence-based choice of therapy and forms the framework for future research.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Kalra S
    -  Sahay R
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed93    
    PDF Downloaded17    

Recommend this journal